Medical Foods for Inborn Errors of Metabolism Market Report 2026

The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $3.46 billion in 2025 to $3.87 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to rising diagnosis of metabolic disorders, expansion of newborn screening programs, increasing clinical adoption of medical foods, availability of specialized dietary formulations, growth of hospital-based nutrition therapy.

The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $6.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising investments in rare disease nutrition, expansion of home-based medical nutrition, growing demand for patient-friendly formulations, increasing regulatory support for medical foods. Major trends in the forecast period include increasing development of disease-specific nutritional formulas, rising adoption of gmp-based medical foods, growing demand for ready-to-use therapeutic nutrition, expansion of personalized nutrition solutions, enhanced focus on clinical efficacy and safety.

The rise in genetic (inherited) disorders is expected to drive the growth of the medical foods for inborn errors of metabolism market going forward. Genetic disorders are diseases caused entirely or partly by deviations from the typical DNA sequence. Medical foods provide specialized nutrition for individuals, particularly infants, with metabolic abnormalities, addressing their unique metabolic needs, preventing nutritional deficiencies, and supporting growth and overall well-being. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, sickle cell disease (SCD) affects about 100,000 people in the United States, with over 90% being non-Hispanic Black or African American, and an estimated 3%-9% Hispanic or Latino. Therefore, the increasing prevalence of genetic disorders is fueling the medical foods for inborn errors of metabolism market.

Product innovation has become a prominent trend in the medical food market for inborn errors of metabolism. Leading companies in this sector are focusing on developing cutting-edge products to enhance their market presence. For instance, in October 2023, Galen Limited, a UK-based pharmaceutical firm, introduced PKU Easy Microtabs Plus as part of its Medical Nutrition line. This product is designed to aid in the dietary management of Phenylketonuria (PKU), a metabolic disorder. PKU Easy Microtabs Plus provides patients with a more convenient and precise way to control their phenylalanine levels through small, easy-to-swallow microtabs. This innovative formulation aims to improve the quality of life for individuals with PKU by facilitating better dose customization and ease of use.

In July 2023, Pentec Health, a US-based provider of specialty infusion services and medical foods, acquired ZOIA Pharma for an undisclosed amount. Through this acquisition, Pentec Health aims to enhance its product portfolio by incorporating the PKU GOLIKE family of medical food products, specifically designed for the dietary management of phenylketonuria (PKU). The PKU GOLIKE range offers patients innovative options to effectively manage their protein intake. ZOIA Pharma is a US-based organization dedicated to developing medical food specifically for inborn errors of metabolism.

Major companies operating in the medical foods for inborn errors of metabolism market are Nestlé Health Science, Abbott Laboratories, Danone SA, Cambrooke Therapeutics, Ajinomoto Co Ltd, Meiji Holdings Co Ltd, PKU Perspectives, Solace Nutrition, Aegle Nutrition, Homestat Farm, Formulaid, Medtrition, Immedica Pharma AB, Phesgo Medical Foods, Helius Medical Nutrition, Vitafriends GmbH, MetaX Institut für Diätetik, Dr Schär AG, Nutricia Milupa GmbH, SHS International Ltd.

North America was the dominant region in the medical foods for inborn errors of metabolism market in 2025. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the medical foods for inborn errors of metabolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The medical food for inborn errors of the metabolism market consists of sales of galactose-free formulas, modified starches and carbohydrate supplements, and Vitamin pyridoxine (B6) supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.